Venus Remedies Receives Marketing Authorization For Bendamustine In Saudi Arabia

Marketing Authorization For Bendamustine In Saudi Arabia strengthens our oncology portfolio in the GCC (Gulf Cooperation Council) and reinforces the commitment to delivering high-quality, technology-intensive cancer therapies across global markets.

Saudi Arabia — the largest pharmaceutical market in the GCC — has always been a strategic focus for us. With multiple marketing authorizations already secured in the country, this latest addition marks another step in our efforts to make complex generics and critical care medicines more widely accessible across the region.

Bendamustine is a vital chemotherapy drug used in the treatment of certain blood cancers, including chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma. With rising cancer incidence across the Middle East, approvals like this carry both clinical relevance and long-term impact.

This authorization aligns with our broader mission: to be a trusted global partner in oncology and critical care by driving access, affordability, and innovation in complex drug segments.